NeuroVigil and Roche Launch Personalized Neurodiagnostics Initiative for Enabling Preventive Treatment of CNS Disorders

SAN DIEGO--(Business Wire)--
Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma
giant Roche announced an agreement regarding a major innovation in collecting
and analyzing data from clinical trials. NeuroVigil will provide Roche with its
iBrain devices and accompanying software analysis services to help speed up
Roche`s drug development for various CNS disorders. NeuroVigil`s advanced
portable, noninvasive iBrainTM devices will be used to monitor neural activity
in outpatient clinical trials. NeuroVigil will analyze the resulting data on a
patient-by-patient basis using the NeuroVigil proprietary software algorithms
and brain derived biomarker libraries to further characterize the compounds from
Roche. These services will enable Roche to detect subtle individual changes in
brain activity at very low drug dosages, often before the onset of cognitive
symptoms and adverse effects.

"NeuroVigil is delighted to join forces with Roche, the world`s largest
diagnostics company, and advance on a path of innovation and discovery, likely
to accelerate the pace at which we can make early and significant contributions
to the lives of many patients suffering from, or about to develop, a major
neuropathological condition," observed Dr. Philip Low, Founder, Chairman and CEO
of NeuroVigil.

About NeuroVigil

NeuroVigil, Inc. is dedicated to the betterment of the human condition by
merging noninvasive wireless brain recording technology with advanced
computational analysis techniques. The award-winning company has developed
proprietary technology which leverages the dynamic oscillations produced during
sleep in order to systematically scan the brain for signs of pathologic activity
years in advance of cognitive or behavioral symptoms. For more information:
www.neurovigil.com

NeuroVigil, Inc.
Emily Polidan, +1-858-454-5134
info@neurovigil.com

Copyright Business Wire 2009